• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在停用疾病修正抗风湿药物时疾病的无活动期似乎会影响幼年特发性关节炎的发作率:一项观察性回顾性研究。

Duration of inactive disease while off disease-modifying anti-rheumatic drugs seems to influence flare rates in juvenile idiopathic arthritis: an observational retrospective study.

机构信息

Universidade Federal de São Paulo - UNIFESP.

Universidade de São Caetano do Sul - USCS.

出版信息

Acta Reumatol Port. 2021 Apr-Jun;46(2):120-125.

PMID:34226433
Abstract

BACKGROUND

many Juvenile Idiopathic Arthritis (JIA) patients reach inactivity while medicated, but there are no guidelines to determine the moment or method for discontinuing medications. We present the flare rates and remission and possible influencing factors after therapy discontinuation in children with JIA.

METHODS

data was collected from charts of JIA patients (n=70) in remission on medication, who had their drugs withdrawn.

RESULTS

Seventy patients fulfilled inclusion criteria and were included for analysis. The mean time of inactive disease on medication until tapering or withdrawal was 15.6±6.7 months; 45 (64.3%) patients remained in remission and 25 (35.7%) flared. There was no difference between groups regarding sex, age, JIA subtype, disease duration, time in remission on medication and scheme of therapy withdrawal. Patients who fulfilled Wallace criteria for remission off medication had lower flare rates than those who did not achieve 12 months of remission after the medication withdrawal (p<0.0001). Patients who used biologic DMARDs plus synthetic DMARDs appeared to flare more (77.8% vs 29.5% respectively, p=0.008) and presented shorter periods of inactivity off medication (15.3±24.7 vs 32.3 ± 31.7 months respectively, p=0.049) compared to those who used only synthetic DMARDs.

CONCLUSION

It is possible that gradual drug tapering is not necessary for JIA patients, but caution must be exerted in those patients using biologic DMARDs, weighing carefully the decision to withdraw medication, due to their higher flare rates and shorter times of inactive disease after the medication withdrawal.

摘要

背景

许多幼年特发性关节炎(JIA)患者在接受药物治疗时达到无活动期,但目前尚无确定停止药物治疗的时机或方法的指南。我们报告了 JIA 患儿停药后出现的复发率、缓解率和可能的影响因素。

方法

从正在接受药物治疗、处于缓解期的 JIA 患儿(n=70)的病历中收集数据,这些患儿的药物已被停用。

结果

70 名患者符合纳入标准并被纳入分析。在药物治疗期间达到无疾病活动期直至逐渐减少或停药的平均时间为 15.6±6.7 个月;45(64.3%)名患者仍处于缓解期,25(35.7%)名患者复发。在性别、年龄、JIA 亚型、疾病持续时间、药物治疗缓解时间和停药方案方面,两组之间没有差异。符合停药时无药物缓解标准的患者复发率低于停药后 12 个月未达到缓解的患者(p<0.0001)。使用生物 DMARDs 联合合成 DMARDs 的患者似乎更容易复发(分别为 77.8%和 29.5%,p=0.008),停药后无疾病活动期的时间更短(分别为 15.3±24.7 个月和 32.3 ± 31.7 个月,p=0.049),与仅使用合成 DMARDs 的患者相比。

结论

对于 JIA 患者,逐渐减少药物剂量可能不是必需的,但对于使用生物 DMARDs 的患者,必须谨慎,仔细权衡停药的决定,因为他们的复发率更高,停药后无疾病活动期的时间更短。

相似文献

1
Duration of inactive disease while off disease-modifying anti-rheumatic drugs seems to influence flare rates in juvenile idiopathic arthritis: an observational retrospective study.在停用疾病修正抗风湿药物时疾病的无活动期似乎会影响幼年特发性关节炎的发作率:一项观察性回顾性研究。
Acta Reumatol Port. 2021 Apr-Jun;46(2):120-125.
2
Discontinuation of biologic DMARDs in non-systemic JIA patients: a scoping review of relapse rates and associated factors.生物制剂 DMARDs 在非系统性幼年特发性关节炎患者中的停药:复发率及相关因素的范围回顾。
Pediatr Rheumatol Online J. 2022 Dec 5;20(1):109. doi: 10.1186/s12969-022-00769-5.
3
Impact of medication withdrawal method on flare-free survival in patients with juvenile idiopathic arthritis on combination therapy.药物撤停方法对接受联合治疗的幼年特发性关节炎患者无疾病发作生存期的影响。
Arthritis Care Res (Hoboken). 2015 May;67(5):658-66. doi: 10.1002/acr.22477.
4
Treatment Withdrawal Following Remission in Juvenile Idiopathic Arthritis: A Systematic Review of the Literature.缓解后治疗撤停在幼年特发性关节炎中的应用:文献系统性综述。
Paediatr Drugs. 2019 Dec;21(6):469-492. doi: 10.1007/s40272-019-00362-6.
5
Predictors of Flare Following Etanercept Withdrawal in Patients with Rheumatoid Factor-negative Juvenile Idiopathic Arthritis Who Reached Remission while Taking Medication.预测类风湿因子阴性幼年特发性关节炎患者在药物治疗达到缓解后停用依那西普后复发的因素。
J Rheumatol. 2018 Jul;45(7):956-961. doi: 10.3899/jrheum.170794. Epub 2018 May 1.
6
When to stop medication in juvenile idiopathic arthritis.何时停止青少年特发性关节炎的药物治疗。
Curr Opin Rheumatol. 2023 Sep 1;35(5):265-272. doi: 10.1097/BOR.0000000000000948. Epub 2023 May 3.
7
Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomised controlled, non-inferiority trial.在类风湿关节炎中,逐渐减少常规合成疾病修饰抗风湿药物至无药物缓解与稳定治疗相比的效果(ARCTIC REWIND):一项开放标签、随机对照、非劣效性试验的 3 年结果。
Lancet Rheumatol. 2024 May;6(5):e268-e278. doi: 10.1016/S2665-9913(24)00021-3. Epub 2024 Apr 4.
8
Clinical remission and subsequent relapse in patients with juvenile idiopathic arthritis: predictive factors according to therapeutic approach.青少年特发性关节炎患者的临床缓解及随后的复发:根据治疗方法的预测因素。
Pediatr Rheumatol Online J. 2021 Aug 21;19(1):130. doi: 10.1186/s12969-021-00607-0.
9
Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis.依那西普治疗复发性幼年特发性关节炎与初始一线治疗同样有效。
Arthritis Res Ther. 2021 Apr 16;23(1):118. doi: 10.1186/s13075-021-02492-0.
10
Disease Recapture Rates After Medication Discontinuation and Flare in Juvenile Idiopathic Arthritis: An Observational Study Within the Childhood Arthritis and Rheumatology Research Alliance Registry.停药后和幼年特发性关节炎发作时疾病复发率:儿童关节炎和风湿病研究联盟注册中心的一项观察性研究。
Arthritis Care Res (Hoboken). 2023 Apr;75(4):715-723. doi: 10.1002/acr.24994. Epub 2022 Dec 21.

引用本文的文献

1
Pediatric Society of the African League Against Rheumatism juvenile idiopathic arthritis recommendations for enthesitis-related arthritis and juvenile psoriatic arthritis.非洲抗风湿病联盟儿科学会关于附着点炎相关关节炎和青少年银屑病关节炎的建议。
Clin Rheumatol. 2025 Mar;44(3):901-922. doi: 10.1007/s10067-025-07334-x. Epub 2025 Feb 1.